Trial reportScientific reports2025
Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness and safety of probiotics in treating knee osteoarthritis: an updated systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Network meta-analysis of metformin, probiotics, krill oil, celecoxib, and glucosamine/chondroitin in the treatment of knee osteoarthritis.Frontiers in medicine · 2026Pooled it
- Effects of gut microbiota-targeted interventions on pain, physical function, and inflammatory biomarkers in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2026Pooled it
- Heat-TreatedCells · 2026Article
- Gut and Joint Microbiome and Dysbiosis: A New Perspective on the Pathogenesis and Treatment of Osteoarthritis.Pathogens (Basel, Switzerland) · 2026Review
- Recent Developments in Osteoarthritis Research: Innovative Therapeutic Approaches and the Role of Polyphenols and Nanotechnology.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knee osteoarthritis (OA) is a prevalent degenerative joint disease among middle-aged and older adults, leading to chronic pain, functional limitations, and decreased quality of life. While probiotics have shown anti-inflammatory potential in preclinical studies, their therapeutic role in OA has not been well established in human research. This exploratory randomized controlled trial (RCT) aimed to evaluate the efficacy and safety of Latilactobacillus sakei LB-P12 in improving knee OA symptoms. In this randomized, double-blind, placebo-controlled trial, 100 participants aged 40-75 years with chronic knee pain were assigned to receive either LB-P12 (350 mg/day, 10 billion CFU) or placebo for 12 weeks. The primary outcome was the change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Secondary outcomes included visual analog scale (VAS) scores for pain, inflammatory markers (CRP, ESR, IL-1β, IL-6, TNF-α), cartilage degradation biomarkers (COMP), joint space width, and health-related quality of life (EQ-5D-5L). Safety was evaluated using laboratory tests and vital signs. After 12 weeks, the LB-P12 group showed significantly greater improvements in WOMAC total scores and VAS pain scores compared to the placebo group. All three WOMAC subdomains-pain, stiffness, and physical function-showed consistent reductions. Inflammatory cytokines, particularly IL-1β, were significantly reduced in the LB-P12 group. Quality of life also improved significantly. No adverse events or clinically meaningful abnormalities in laboratory values were observed. This exploratory RCT suggests that daily supplementation with LB-P12 is safe and may offer potential benefits in reducing knee pain and improving physical function and quality of life in individuals with knee OA. Further large-scale and long-term RCTs are needed to confirm these findings and elucidate the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.